Loading company
Passage BIO, Inc.
PASG · Nasdaq · ·
Next earnings: November 9, 2026
$4.67+2.0%Sep 29 close
- 1M
- +3.3%
- 6M
- -24.4%
- 1Y
- -41.8%
- 5Y
- -97.8%
PASG · Nasdaq · ·
Next earnings: November 9, 2026
$4.67+2.0%Sep 29 close
Passage BIO, Inc. is scheduled to report next on November 9, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$7.8M | -$9.4M | +16.66% |
| Profit per share | -$2.44 | -$2.96 | +17.57% |
| Free Cash Flow | -$8.5M | -$22.5M | +62.36% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Passage BIO, Inc. has no earnings call transcript available.
“We are proud of the progress made in 2025 as we meaningfully advanced our PBFT02 clinical program for the treatment of genetic forms of frontotemporal dementia,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Bio Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression. To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: passagebio.com .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Passage BIO, Inc.’s Item 2.02 8-K filed March 3, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.